Navigation Links
New target for medicine to combat Alzheimer's: VIB scientists confirm protein's key role
Date:2/12/2009

Alzheimer's disease

Two thirds of all patients with dementia suffer from Alzheimer's disease. Estimates indicate that by 2010 our country will have more than 150,000 Alzheimer's patients. Alzheimer's is a disease that gradually destroys brain cells, with the result that the mental capacity of patients with Alzheimer's gradually declines. At first, memory begins to fail, but the patient's cognitive capabilities also deteriorate as the disease progresses. Today, this disease cannot yet be cured. Current medicines for Alzheimer's patients sustain the memory functions for a short time, but they are unable to stop the brain cells from dying off. At best, they are able to limit the loss of memory during the early phases of the disease.

The β-amyloid cascade

The brains of Alzheimer's patients typically show the presence of amyloid plaques, which are abnormal accumulations of a protein (β-amyloid) between the neurons. The sticky β-amyloid develops when the precursor protein (amyloid precursor protein or APP) is cut into pieces incorrectly.

GPR3: target for new medicine

Several years ago, Bart De Strooper and other researchers elucidated the way in which these plaques originate and discovered that secretases play a large role in this process. Now, under the direction of Bart De Strooper, and in collaboration with researchers from the biotech company Galapagos, Amantha Thathiah and her colleagues have investigated whether additional substances are also involved in the development of the plaques. Which is apparently the case: Galapagos has identified the GPR3 protein as a new player. The VIB researchers have been able to show − in vitro (in cells isolated and studied in the laboratory) as well as in vivo (in living animals − mice, in this instance) − that blocking GPR3 leads to reduction of the plaques.

Importance of this research

The GPR3 protein is an important target molecule for the eventual development of a new medicine against Alzheimer's disease. The majority of all of the medicines that are available in pharmacies − regardless of the disease that they work against − act on proteins of a specific type. GPR3 is one of these − which, at this time, cannot be said for any other protein implicated in Alzheimer's.

Further research and development of this medicine will be carried out by the Flemish biotechnology company Galapagos. It is possible that 'the cure for Alzheimer's' will never be able to restore a patient's memory − but, hopefully, the disorder can be arrested, saving as many brain cells as possible.


'/>"/>

Contact: Pieter Van Dooren
info@vib.be
329-244-6611
VIB (the Flanders Institute for Biotechnology)
Source:Eurekalert

Related biology news :

1. Nicotinic receptors may be important targets for treatment of multiple addictions
2. New target for anti-flu drug development
3. Central targets may hinder wider waste management objectives
4. St. Jude finds factors that accelerate resistance to targeted therapy in lymphoblastic leukemia
5. UIC researchers find promising new targets for antibiotics
6. Targeting nerve growth factor may cure liver cancer
7. Study by Pittsburgh researchers identifies possible vaccine target for chlamydia
8. Linchpin gene may be useful target for new breast cancer therapies
9. Gene-targeting pioneer Mario Capecchi shares 2007 Nobel Prize in Medicine
10. Study reveals a key to blood vessel growth and possible drug target
11. Microarray sequence capture speeds large-scale resequencing of targeted genomic regions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/5/2017)... LONDON , April 4, 2017 KEY ... is anticipated to expand at a CAGR of 25.76% ... neurodegenerative diseases is the primary factor for the growth ... full report: https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The ... of product, technology, application, and geography. The stem cell ...
(Date:3/30/2017)... 30, 2017 Trends, opportunities and forecast in ... by technology (fingerprint, AFIS, iris recognition, facial recognition, hand ... by end use industry (government and law enforcement, commercial ... banking, and others), and by region ( North ... Asia Pacific , and the Rest of ...
(Date:3/24/2017)... Research and Markets has announced the addition ... Trends - Industry Forecast to 2025" report to their offering. ... The Global Biometric ... of around 15.1% over the next decade to reach approximately $1,580 ... market estimates and forecasts for all the given segments on global ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... ... 2017 , ... A new study published in Fertility and ... in vitro fertilization (IVF) transfer cycles. The multi-center matched cohort study ... comparing the results from the fresh and frozen transfer cohorts, the authors of ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... conjugate (ADC) therapeutics, today confirmed licensing rights that give it exclusive global ... technology developed in collaboration with Children’s Hospital Los Angeles (CHLA). Additionally, ...
(Date:10/10/2017)... firm Parks Associates announced today that Tom Kerber , ... Meeting , October 11 in Scottsdale, Arizona . Kerber ... smart safety and security products impact the competitive landscape. ... Parks Associates: Smart Home Devices: Main Purchase Driver ... "The residential security market has experienced continued growth, and the introduction ...
(Date:10/10/2017)... ... October 10, 2017 , ... The ... prestigious awards honoring scientists who have made outstanding contributions to analytical ... during Pittcon 2018, the world’s leading conference and exposition for laboratory science, which ...
Breaking Biology Technology: